Most patients who stop Wegovy regain a significant portion of lost weight within one year, and hunger and cravings typically return as the drug clears the body. Clinical trial data and patient accounts tell a consistent story: the benefits of semaglutide are largely tied to continued use, which is why the decision to stop deserves a careful conversation with your prescriber.
What Does the Clinical Research Actually Show?
The most cited evidence comes from the STEP 4 withdrawal trial, published in Diabetes, Obesity and Metabolism (Wilding et al., 2022). Participants who had already lost weight on semaglutide 2.4 mg were switched to placebo for 48 weeks. On average, they regained about two-thirds of their prior weight loss — roughly 12 percentage points of body weight — within that one-year window. Cardiometabolic markers such as waist circumference, blood pressure, and blood glucose also returned toward pre-treatment levels.
This is not a personal failure. Obesity is now classified as a chronic disease by the American Medical Association, and semaglutide works by continuously suppressing appetite signals in the brain. When the drug is gone, those signals resume.
What Do Patients Actually Experience Week by Week?
Individual timelines vary, but semaglutide's half-life of approximately one week means the drug takes roughly four to five weeks to fully clear the body. Most patients report noticeable appetite changes within the first two to four weeks after the final dose.
| Timeframe After Last Dose | What Many Patients Report | What Clinical Data Suggests |
|---|---|---|
| Weeks 1–2 | Little change; some feel the same as on the drug | Drug still present at meaningful levels (half-life ~7 days) |
| Weeks 3–4 | Hunger returning, larger portion sizes feel normal again | Semaglutide largely cleared; appetite suppression fading |
| Weeks 5–8 | Cravings increase, food "noise" comes back, some emotional eating resumes | Early weight regain begins in STEP 4 trial data |
| Months 3–6 | Noticeable scale movement upward; frustration common | Average regain of ~7–8% body weight in STEP 4 by week 20 |
| Months 6–12 | Weight plateau or continued regain; some report stabilizing with lifestyle changes | ~12 percentage-point weight regain by week 48 (STEP 4) |
| 12 Months+ | Variable — some maintain partial loss, many return near baseline | Cardiometabolic markers also largely reversed toward baseline |
Why Does Appetite Return So Strongly?
Semaglutide mimics GLP-1, a hormone released in the gut after eating. It slows gastric emptying, increases feelings of fullness, and acts on receptors in the brain's hypothalamus to reduce hunger. According to the FDA prescribing information for Wegovy, these effects are pharmacological — meaning they exist because the drug is present. When semaglutide is no longer in your system, the underlying biology that drove appetite before treatment is still there. For most people, the brain's hunger signaling simply picks up where it left off.
Many patients describe the return of "food noise" — the persistent mental preoccupation with eating — as one of the most difficult parts of stopping. This is a recognized neurological phenomenon, not a lack of willpower.
The most important thing to know: Weight regain after stopping Wegovy is a documented, expected physiological response — not a personal failure. The STEP 4 trial showed that two-thirds of lost weight returned within one year in patients who discontinued, even those who had maintained healthy behaviors.
Can Lifestyle Changes Slow the Regain?
Some patients do maintain a portion of their weight loss after stopping, particularly those who used the medication window to build durable habits. Evidence from the STEP trials suggests that structured diet and exercise counseling provided alongside semaglutide led to better outcomes, but no lifestyle intervention has been shown to fully replicate the drug's appetite-suppressing effect once it is gone.
- Protein-forward eating patterns may help blunt hunger signals naturally, as protein is the most satiating macronutrient.
- Resistance training can help preserve muscle mass that may have been lost during weight loss on the drug.
- Sleep and stress management influence ghrelin and cortisol, both of which drive appetite — managing these can reduce how pronounced returning hunger feels.
- Tracking food and weight gives early warning of regain trends, allowing faster course correction.
None of these are substitutes for medication in people whose obesity has a strong biological driver, but they can meaningfully slow the trajectory of regain for some individuals.
What Are the Options If You Want to Restart or Switch?
Many patients and prescribers choose to view Wegovy — or its higher-dose sibling Zepbound (tirzepatide) — as long-term or indefinite therapy, similar to how statins or antihypertensives are managed. If stopping was driven by cost, shortage, or side effects, it may be worth revisiting those specific barriers rather than accepting regain as inevitable. Options that patients commonly discuss with their prescribers include:
- Restarting semaglutide at a lower dose and re-titrating
- Switching to tirzepatide (Zepbound/Mounjaro), which targets both GLP-1 and GIP receptors and has shown strong weight-loss results in the SURMOUNT trials
- Exploring manufacturer savings programs or compounding pharmacy options (note: FDA has warned about quality concerns with compounded semaglutide)
- Transitioning to a structured medical weight management program with a bariatric specialist
Frequently Asked Questions
Deciding to stop Wegovy — whether because of cost, shortages, side effects, or personal choice — is a significant medical decision with real physiological consequences. The science is clear that weight regain is the expected outcome for most people, but your individual experience depends on many factors including your underlying health, how long you were on the medication, and what habits you built along the way. Speak with your prescriber before stopping, when stopping, and in the months that follow — so that any regain is caught early and your options remain open.
- Wilding JPH et al. 'Weight regain and cardiometabolic effects after withdrawal of semaglutide.' Diabetes, Obesity and Metabolism, 2022. doi:10.1111/dom.14725
- FDA Wegovy (semaglutide) Prescribing Information, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
- Rubino DM et al. 'Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity.' JAMA, 2022. doi:10.1001/jama.2022.7621
- NIH National Institute of Diabetes and Digestive and Kidney Diseases. 'Overweight & Obesity Statistics.' https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity